<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with stigmatization and social rejection. As a result, their quality of life is significantly impaired. Biological therapies have revolutionized the treatment of moderate to severe psoriasis. The aim of this paper is to look over the most important biological therapies available for the management of plaque-type psoriasis.</p></abstract>

Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with stigmatization and social rejection. As a result, their quality of life is significantly impaired. Biological therapies have revolutionized the treatment of moderate to severe psoriasis. The aim of this paper is to look over the most important biological therapies available for the management of plaque-type psoriasis.

Biological therapies in psoriasis - revisited

“Carol Davila” University of Medicine and Pharmacy

“Victor Babeş” Hospital of Infectious and Tropical Diseases, Dermatology Department

“Hexamed” Clinic, Ophthalmology Department

“Colentina” Clinical Hospital, Dermatology Department I

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Biological therapies in psoriasis - revisited"}

Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with...

Biological therapies in psoriasis - revisited

Publié en ligne: 17 mai 2018

Pages: 75 - 84

Reçu: 09 nov. 2017

DOI: https://doi.org/10.1515/rjim-2017-0045

Mots clés
psoriasis, biological therapies, TNF-α, IL-17, anti-IL-12/23

© 2018 Maria-Isabela Sârbu et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Biological therapies in psoriasis - revisited

Publié en ligne: 17 mai 2018

Pages: 75 - 84

Reçu: 09 nov. 2017

DOI: https://doi.org/10.1515/rjim-2017-0045

Mots cléspsoriasis, biological therapies, TNF-α, IL-17, anti-IL-12/23

© 2018 Maria-Isabela Sârbu et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
psoriasis, biological therapies, TNF-α, IL-17, anti-IL-12/23